Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Content from MarketBeat Media Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They BoughtSubmitted by Thomas Hughes. Date Posted: 12/30/2025. 
Summary - Multiple leadership teams stepped in to buy in 2025—but the timing and pattern of those buys matter more than the headline count.
- One of the five names looks like a classic “insiders see value” setup, while another reads more like a risk tell than a green flag.
- The biggest 2026 decision point across the list isn’t insider activity—it’s whether a few specific catalysts break the right way.
Insider buying is an important metric for investors because it can indicate C-suite confidence in operations, growth, and profitability. Clustered insider buying — when multiple executives and directors buy around the same time — can be even more informative, as it suggests shared conviction rather than a one-off trade. The goal isn't to "buy because insiders bought." Use 2025 insider activity as a screening tool, then evaluate whether each name has the fundamentals, catalysts, and valuation setup that make it a smart watchlist candidate for 2026. Insiders Like Matador Resources Cash Flow, Growth, and Capital Return What No One's Saying About Amazon's 30k Layoff
First they cut jobs at Meta... now 30,000 at Amazon – its largest layoff in history. What's happening inside these Mag 7 companies, particularly as the stocks continue to soar to all- time highs? The same former hedge fund manager who predicted the dot com crash, the housing crisis and the fall of Lehman is now stepping forward to explain what's really going on... and what you should be doing with your money Learn more. Matador Resources (NYSE: MTDR) is familiar to InsiderTrades readers. It has ranked highly on lists of insider buying for years and was the top stock insiders bought in 2025. Fifteen insiders — including the CEO, COO, CAO, an EVP, and several directors — made more than 50 purchases in 2025, bringing their combined holdings to over 5% of the company. The capital return is attractive, yielding more than 3.5% at year-end 2025 and appearing sustainable. It pays less than 20% of earnings, which, combined with its growth trajectory, allows for aggressive annual increases. Matador often raises distributions more than once per year and has posted a high double-digit distribution CAGR. Institutions own more than 90% of the stock and were accumulating in 2025, while analysts rate it a Moderate Buy with roughly 40%–50% upside potential. 
MicroStrategy's Insider Activity Highlights the Risk MicroStrategy (NASDAQ: MSTR) was the second-most-bought stock by insiders in 2025, with eight insiders buying in 21 transactions. However, purchases were far outweighed by sales, indicating a mass exodus from the stock. Contributing factors include persistent dilutive efforts to raise capital for Bitcoin purchases, high debt and servicing costs, Bitcoin volatility, reduced net asset value (NAV), and the risk of exclusion from major indices. Institutions that had been accumulating reverted to selling in Q4, weighing on the stock's price at year-end. 
Shoulder Innovations Insiders Signal Confidence Shoulder Innovations (NYSE: SI) has a spotty history and completed an IPO in 2025. The key takeaway is that insiders — including the CEO, CFO, directors, and major shareholders — bought shares following the IPO, signaling strong confidence in the company's prospects. That activity made it the third-most-bought stock by insiders in 2025. The company produces specialized next-generation shoulder-replacement technology and is on track to sustain high-20% revenue growth over the next three to five years. Institutions, which own roughly 85% of the stock, are accumulating, and analysts have become more constructive: they rate it a Moderate Buy, raised price targets in Q4, and show about 35% consensus upside. 
Smithfield Foods Insiders Buy Into Value and Growth Opportunity Smithfield Foods (NASDAQ: SFD) executives bought heavily in Q3 2025, putting the company fourth for insider purchases that year. Their buying coincided with a secondary stock offering and signaled confidence in Smithfield's growth trajectory, value, and yield potential. Trading at roughly 10x earnings, SFD trades well below consumer staples peers such as Hormel, suggesting a potential 50% move if valuation converges. The dividend yielded about 4.4% at year-end 2025 and is likely to increase over time. Institutions and corporate owners — which control about 98% of shares — accumulated in 2025, and analysts forecast double-digit upside in 2026. 
Rezolute, Inc. Fails to Pass Critical Hurdle Despite Insider Confidence Rezolute, Inc. (NASDAQ: RZLT) is a late-stage biopharma developing treatments for hyperinsulinism. Insiders showed strong conviction early in 2025, with the CEO, CFO, and directors making multiple purchases. However, those buys preceded clinical trial results that showed the lead candidate did not work as intended. Another trial is underway, but results aren't expected until H2 2026 at the earliest. Analysts have since slashed price targets, capping near-term upside potential. 
| 
Post a Comment
Post a Comment